RECURRENT BACTERIAL VAGINOSIS: POSSIBILITY OF INCREASING THE DURATION OF REMISSION

Objective. To investigate the efficiency and antirecurrent activity of adjuvant therapy with Multi-Gyn actigel for bacterial vaginosis (BV) in reproductive-aged women. Subjects and methods. The investigation covered 50 female patients, whose mean age was 18 to 45 years (29.6±4.5 years), with a clinical diagnosis of BV confirmed by real-time polymerase chain reaction (Femoflor-16 real-time PCR). The patients were randomized into two equal groups of 25 subjects in each. Group 1 received one-dose vaginal clindamycin cream overnight for 10 days and, as therapy stage 2, the actigel 2 mg twice daily for 10 days. Group 2 used one-dose vaginal clindamycin cream overnight for 10 days and, as therapy stage 2, a drug containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 for 14 days. Results. The therapeutic effectiveness was 92% (n = 46) in both groups. However, the more sustained remission rates were 88% (n = 22) in the group of patients receiving adjuvant therapy with Multi-Gyn actigel and 64% (n = 16) in the comparison group (p < 0.5). Conclusion. Long-term adjuvant Multi- Gyn actigel therapy in conjunction with etiotropic therapy was associated with a longer recurrent BV-free interval. Addition of Multi-Gyn actigel considerably improved treatment results. Drugs that contain probiotic Lactobacilli are also effective in the combination therapy of BV; however, their efficacy is based on their longer use.

bacterial vaginosis, actigel, key cells